RUMORED BUZZ ON HEMGENIX

Quantity of qualified people: CDEC mentioned the uncertainty in the amount of people with moderately severe to critical hemophilia B in Canada eligible for etranacogene dezaparvovec. Medical experts consulted by CADTH indicated that some sufferers that are categorized as possessing delicate or moderate disease may have a serious bleeding phenotype,